Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy

Antiviral Chemistry and Chemotherapy

Volumn 22, Issue 5, 2012, Pages 181-203

  Pertusati, Fabrizio ^a   Serpi, Michaela ^a   Mcguigan, Christopher ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DIAMINOPURINE DERIVATIVE; 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ACYCLIC NUCLEOSIDE; ADEFOVIR; ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; ARYL PHOSPHONAMIDATE PRODRUG; CYCLIC 1 ARYL 1,3 PROPANYL ESTER PRODRUG; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GUANOSINE PHOSPHATE; LAMIVUDINE; PHOSPHONIC ACID DERIVATIVE; PHOSPHONODIAMIDATE PRODRUG; PRADEFOVIR; PRODRUG; S ACYLTHIOETHYL ESTER PRODRUG; SALICYLIC ACID DERIVATIVE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VALACICLOVIR; VALGANCICLOVIR; XANTHINE OXIDASE;

ADENOVIRUS 2; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; ENZYME PHOSPHORYLATION; FIRST PASS EFFECT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN HERPESVIRUS 6; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CLEARANCE; LIPOPHILICITY; NONHUMAN; PAPILLOMAVIRUS INFECTION; POXVIRUS; PRIORITY JOURNAL; REVIEW; SARCOMA VIRUS; VACCINIA VIRUS; VARICELLA ZOSTER VIRUS; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; MICROBIAL SENSITIVITY TESTS; NUCLEOSIDES; PHOSPHONIC ACIDS; PRODRUGS;

EID: 84863113618     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2012     Document Type: Review

References (84)

1. De Clercq E, Neyts J. Antiviral agents acting as DNA or RNA chain terminators. Handb Exp Pharmacol 2009; 189:53-84.
2. De Clercq E. The clinical potential of the acyclic (and cyclic) nucleoside phosphonates. The magic of the phosphonate bond. Biochem Pharmacol 2011; 82:99-109.
3. De Clercq E, Holý A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov 2005; 4:928-940.
4. Holý A. Phosphonomethoxyalkyl analogs of nucleotides. Curr Pharm Des 2003; 9:2567-2592.
5. De Clercq E, Holý A, Rosenberg I, et al. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986; 323:464-467.
6. De Clercq E, Andrei G, Balzarini J, et al. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines. Nucleosides Nucleotides Nucleic Acids 2005; 24:331-341.
7. De Clercq E. In search of a selective antiviral chemotherapy. Clin Microbiol Rev 1997; 10:674-693.
8. De Clercq E. The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. Antiviral Res 2007; 75:1-13.
9. De Clercq E, Neyts J. Therapeutic potential of nucleoside/ nucleotide analogues against poxvirus infections. Rev Med Virol 2004; 14:289-300.
10. Dal Pozzo F, Andrei G, Holy A, et al. Activities of acyclic nucleoside phosphonates against orf virus in human and ovine cell monolayers and organotypic ovine raft cultures. Antimicrob Agents Chemother 2005; 49:4843-4852.
11. Naesens L, Lenaerts L, Andrei G, et al. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother 2005; 49:1010-1016.
12. Krečmerová M, Holý A, Pskala A, et al. Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (Cidofovir) and related compounds. J Med Chem 2007; 50:1069-1077.
13. Cundy KCBA, Lynch G, Shaw JP, et al. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab Dispos 1996; 24:745-752.
14. Mendel DB, Chilar T, Moon K, Chen MS. Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl) methyl] cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase. Antimicrob Agents Chemother 1997; 41:641-646.
15. Naesens L, Balzarini J, Rosenberg I, et al. 9-(2-Phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP): a novel agent with anti-human immunodefciency virus activity in vitro and potent anti-Moloney murine sarcoma virus activity in vivo. Eur J Clin Microbiol Infect Dis 1989; 8:1043-1047.
16. Ying C, De Clercq E, Neyts J. Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture. J Viral Hepat 2000; 7:79-83.
17. Ying C, De CE, Nicholson W, et al. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000; 7:161-165.
18. Kramata P, Votruba I, Otova B, et al. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases a, d, and e. Mol Pharmacol 1996; 49:1005-1011.
19. Kreider JW, Balogh K, Olson RO, et al. Treatment of latent rabbit and human papillomavirus infections with 9-(2-phosphonylmethoxy)ethylguanine (PMEG). Antiviral Res 1990; 14:51-58.
20. Holý A, Votruba I, Masojidkova M, et al. 6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity. J Med Chem 2002; 45:1918-1929.
21. Balzarini J, Pannecouque C, De Clercq E, et al. Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonates. Antimicrob Agents Chemother 2002; 46:2185-2193.
22. Wu T, Froeyen M, Kempeneers V, et al. Deoxythreosyl phosphonate nucleosides as selective anti-HIV agents. J Am Chem Soc 2005; 127:5056-5065.
23. Mackman RL, Zhang L, Prasad V, et al. Synthesis and anti-HIV activity of cyclic pyrimidine phosphonomethoxy nucleosides and their prodrugs: a comparison of phosphonates and corresponding nucleosides. Nucleosides Nucleotides Nucleic Acids 2007; 26:573-577.
24. Cihlar T, Ray AS, Boojamra CG, et al. Design and profling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodefciency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131. Antimicrob Agents Chemother 2008; 52:655-665.
25. Li F, Maag H, Alfredson T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci 2008; 97:1109-1134.
26. Krise J P, Stella VJ. Prodrugs of phosphates, phosphonates, and phosphinates. Adv Drug Deliv Rev 1996; 19:287-310.
27. Hecker SJ, Erion MD. Prodrugs of phosphates and phosphonates. J Med Chem 2008; 51:2328-2345.
28. He G-X, Krise JP, Oliyai R. Prodrugs of phosphonates, phosphinates, and phosphates. Prodrug challenges and rewards part 1 and part 2. New York: Springer 2007; pp. 223-264.
29. Schultz C. Prodrugs of biologically active phosphate esters. Bioorg Med Chem 2003; 11:885-898.
30. Ariza ME. Current prodrug strategies for the delivery of nucleotides into cells. Drug Des Rev Online 2005; 2:373-387.
31. Peterson LW, McKenna CE. Prodrug approaches to improving the oral absorption of antiviral nucleotide analogues. Expert Opin Drug Deliv 2009; 6:405-420.
32. Wagner CR, Iyer VV, McIntee EJ. Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides. Med Res Rev 2000; 20:417-451.
33. Starrett JE, Jr., Tortolani DR, Russell J, et al. Oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy) ethyl]adenine (PMEA). J Med Chem 1994; 37:1857-1864.
34. Zídek Z, Kmoníčková E, Holý A. Cytotoxicity of pivoxil esters of antiviral acyclic nucleoside phosphonates: adefovir dipivoxil versus adefovir. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005; 149:315-319.
35. Smedley J. Is formaldehyde an important cause of allergic respiratory disease? Clin Exp Allergy 1996; 26:247-249.
36. Yu PH, Zuo DM. Formaldehyde produced endogenously via deamination of methylamine. A potential risk factor for initiation of endothelial injury. Atherosclerosis 1996; 120:189-197.
37. Brass EP. Pivalate-generating prodrugs and carnitine homeostasis in man. Pharmacol Rev 2002; 54:589-598.
38. Srinivas RV, Robbins BL, Connelly MC, et al. Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates. Antimicrob Agents Chemother 1993; 37:2247-2250.
39. Choi J-R, Cho D-G, Roh KY, et al. A novel class of phosphonate nucleosides. 9-[(1-phosphonomethoxycyclopropyl)methyl]guanine as a potent and selective anti-HBV agent. J Med Chem 2004; 47:2864-2869.
40. Yuen M-F, Kim J, Kim R, et al. A randomized placebo-controlled, dose-fnding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antivir Ther 2006; 11:977-983.
41. Krečmerová M, Holý A, Andrei G, et al. Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy) propyl]-2,6-diaminopurine (HPMPDAP) as anti-poxvirus agents. J Med Chem 2010; 53:6825-6837.
42. Topalis D, Pradère U, Roy V, et al. Novel antiviral C5-substituted pyrimidine acyclic nucleoside phosphonates selected as human thymidylate kinase substrates. J Med Chem 2011; 54:222-232.
43. Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 2009; 82:A84-A98.
44. Beadle JR, Hartline C, Aldern KA, et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother 2002; 46:2381-2386.
45. Hostetler KY. Synthesis and early development of hexadecyloxypropyl-cidofovir: an oral antipoxvirus nucleoside phosphonate. Viruses 2010; 2:2213-2225.
46. Kern ER, Hartline C, Harden E, et al. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother 2002; 46:991-995.
47. Kern ER, Collins DJ, Wan WB, et al. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004; 48:3516-3522.
48. Quenelle DC, Collins D, Wan W, et al. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004; 48:404-412.
49. Buller RM, Owens G, Schriewer J, et al. Effcacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 2004; 318:474-481.
50. Trost LC, Lampert BM, Robertson A, et al. Interspecies comparison of the pharmacokinetics of CMX001, a lipid conjugated nucleotide analog with broad dsDNA antiviral activity. 23th ICAR Annual Meeting. 25-28 April 2010, San Francisco, CA, USA.
51. Quenelle DC, Collins DJ, Herrod BP, et al. Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice. Antimicrob Agents Chemother 2007; 51:3940-3947.
52. Beadle JR, Wan WB, Ciesla SL, et al. Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses. J Med Chem 2006; 49:2010-2015.
53. Quenelle DC, Collins DJ, Pettway LR, et al. Effect of oral treatment with (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA on replication of murine cytomegalovirus (MCMV) or human cytomegalovirus (HCMV) in animal models. Antiviral Res 2008; 79:133-135.
54. Krečmerová M, Holý A, Pohl R, et al. Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity. J Med Chem 2007; 50:5765-5772.
55. Tichý T, Andrei G, Dracínský M, et al. New prodrugs of adefovir and cidofovir. Bioorg Med Chem 2011; 19:3527-3539.
56. Lebeau I, Andrei G, Dal Pozzo F, et al. Activities of alkoxyalkyl esters of cidofovir (CDV), cyclic CDV, and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against orthopoxviruses in cell monolayers and in organotypic cultures. Antimicrob Agents Chemother 2006; 50:2525-2529.
57. Oliyai R, Arimilli MN, Jones RJ, et al. Pharmacokinetics of salicylate ester prodrugs of cyclic HPMPC in dogs. Nucleosides Nucleotides Nucleic Acids 2001; 20:1411-1414.
58. Oliyai R, Shaw J-P, Sueoka-Lennen CM, et al. Aryl ester prodrugs of cyclic HPMPC. I: physicochemical characterization and in vitro biological stability. Pharm Res 1999; 16:1687-1693.
59. Serafnowska HT, Ashton RJ, Bailey S, et al. Synthesis and in vivo evaluation of prodrugs of 9-[2-(phosphonomethoxy) ethoxy]adenine. J Med Chem 1995; 38:1372-1379.
60. Shaw J-P, Louie MS, Krishnamurthy VV, et al. Pharmakokinetics and metabolism of selected prodrugs of PMEA in rats. Drug Metab Dispos 1997; 25:362-366.
61. Meier C, Görbig U, Müller C, et al. cycloSal-PMEA and cycloAmb-PMEA: potentially new phosphonate prodrugs based on the cycloSal-Pronucleotide approach. J Med Chem 2005; 48:8079-8086.
62. Görbig U, Balzarini J, Meier C. New cycloAMB-nucleoside phosphonate prodrugs. Nucleosides Nucleotides Nucleic Acids 2007; 26:831-834.
63. Benzaria S, Pelicano H, Johnson R, et al. Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy) ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability. J Med Chem 1996; 39:4958-4965.
64. Périgaud C, Gosselin G, Lefebvre I, et al. Rational design for cytosolic delivery of nucleoside monphosphates: 'SATE' and 'DTE' as enzyme-labile transient phosphate protecting groups. Bioorg Med Chem Lett 1993; 3:2521-2526.
65. Li H, Hong JH. Synthesis and anti-HIV evaluation of new acyclic phosphonate nucleotide analogues and their bis(SATE) derivatives. Nucleosides Nucleotides Nucleic Acids 2010; 29:581-590.
66. Ballatore C, McGuigan C, De Clercq E, et al. Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA. Bioorg Med Chem Lett 2001; 11:1053-1056.
67. Birkus G, Kutty N, He G-X, et al. Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol Pharmacol 2008; 74:92-100.
68. Birkus G, Wang R, Liu X, et al. Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrob Agents Chemother 2007; 51:543-550.
69. Mackman RL, Ray AS, Hui HC, et al. Discovery of GS-9131: design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148. Bioorg Med Chem 2010; 18:3606-3617.
70. Ray AS, Vela JE, Boojamra CG, et al. Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodefciency virus agent. Antimicrob Agents Chemother 2008; 52:648-654.
71. Keith KA, Hitchcock MJ, Lee WA, et al. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication. Antimicrob Agents Chemother 2003; 47:2193-2198.
72. Wolfgang GHI, Shibata R, Wang J, et al. GS-9191, a novel topical prodrug of the nucleotide analog PMEG (9-(2-phosphonylmethoxyethyl) guanine), with anti-proliferative activity and possible utility in the treatment of HPV lesions. Antimicrob Agents Chemother 2009; 53:2777-2784.
73. Jansa P, Baszczyňski O, Dračínský M, et al. A novel and effcient one-pot synthesis of symmetrical diamide (bis-amidate) prodrugs of acyclic nucleoside phosphonates and evaluation of their biological activities. Eur J Med Chem 2011; 46:3748-3754.
74. Serpi M, Krylov IS, Zakharova VM et al. Synthesis of peptidomimetic conjugates of cyclic nucleoside phosphonates. Curr Protoc Nucleic Acid Chem 2010; 43:15.4.1-15.4.13.
75. McKenna CE, Kashemirov BA, Eriksson U, et al. Cidofovir peptide conjugates as prodrugs. J Organomet Chem 2005; 690:2673-2678.
76. Eriksson U, Peterson LW, Kashemirov BA, et al. Serine peptide phosphoester prodrugs of cyclic cidofovir: synthesis, transport, and antiviral activity. Mol Pharm 2008; 5:598-609.
77. Eriksson U, Hilfnger JM, Kim J-S, et al. Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir. Bioorg Med Chem Lett 2007; 17:583-586.
78. Peterson LW, Sala-Rabanal M, Krylov IS, et al. Serine side chain-linked peptidomimetic conjugates of cyclic HPMPC and HPMPA: synthesis and interaction with hPEPT1. Mol Pharm 2010; 7:2349-2361.
79. Peterson LW, Kim J-S, Kijek P, et al. Synthesis, transport and antiviral activity of Ala-Ser and Val-Ser prodrugs of cidofovir. Bioorg Med Chem Lett 2011; 21:4045-4049.
80. Zakharova VM, Serpi M, Krylov IS, et al. Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies. J Med Chem 2011; 54:5680-5693.
81. Fu X, Jiang S, Li C, et al. Design and synthesis of novel bis(L-amino acid) ester prodrugs of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) with improved anti-HBV activity. Bioorg Med Chem Lett 2007; 17:465-470.
82. Erion MD, Reddy KR, Boyer SH, et al. Design, synthesis, and characterization of a series of cytochrome P450 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J Am Chem Soc 2004; 126:5154-5163.
83. Reddy KR, Matelich MC, Ugarkar BG, et al. Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B. J Med Chem 2008; 51:666-676.
84. Tillmann HL. Pradefovir, a liver-targeted prodrug of adefovir against HBV infection. Curr Opin Investig Drugs 2007; 8:682-690.